Crossing these mice with the previously reported TCL1 transgenic mouse [42], an established B-CLL mouse model, or the BCL6 transgenic mouse, an established model that recapitulated human DLBCL, may provide suitable model systems to investigate the deregulation of the p53 pathway induced by the Mdm2SNP309 allele and its impact on leukemogenesis and lymphomagenesis while prospective studies in patients with these hematological malignancies are conducted. This evidence concerns the gene TP53 and hematologic disorder.